CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (CAPITAL DEFICIENCY) - USD ($) $ in Thousands		Common Stock	Additional Paid-in Capital Adjustment	Additional Paid-in Capital	Accumulated Deficit Adjustment	Accumulated Deficit	Adjustment	Total
Beginning balance at Dec. 31, 2022		$ 54		$ 379,167		$ (389,861)		$ (10,640)
Beginning balance (in shares) at Dec. 31, 2022	[1]	53,790,167
Issuance of common stock under the Sales Agreement, net		$ 8		14,225				14,233
Issuance of common stock under the Sales Agreement, net (in shares)	[1]	8,212,482
Share-based compensation related to stock options				453				453
Share-based compensation related to restricted stock awards				93				93
Net Income (Loss)						(3,131)		(3,131)
Ending balance at Mar. 31, 2023		$ 62		393,938		(392,992)		1,008
Ending balance (in shares) at Mar. 31, 2023	[1]	62,002,649
Beginning balance at Dec. 31, 2023		$ 73		415,045		(381,549)		33,569
Beginning balance (in shares) at Dec. 31, 2023	[1]	72,952,124
Share-based compensation related to stock options				500				500
Share-based compensation related to restricted stock awards				481				481
Share-based compensation related to restricted stock awards (in shares)	[1]	100,000
Net Income (Loss)						(4,595)		(4,595)
Ending balance (ASU 2020-06) at Mar. 31, 2024			$ (393)		$ 224		$ (169)
Ending balance at Mar. 31, 2024		$ 73		$ 415,633		$ (385,920)		$ 29,786
Ending balance (in shares) at Mar. 31, 2024	[1]	73,052,124

[1] Common stock, $0.001 par value; Authorized – as of March 31, 2024 and December 31, 2023 – 185,000,000 shares.